Aranesp Gets Advisory Committee Boost As Amgen Braces For Labeling Negotiations
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA panel votes against reducing of darbepoietin alfa in patients with failing kidneys who are headed toward dialysis.
You may also be interested in...
Can Amgen Stop The Bleeding As FDA Presses For A Low-Dose Aranesp Trial?
CardioRenal Advisory Committee will discuss whether there should be a trial testing lower dosing limits in CKD patients. With sales declines a forgone conclusion regardless, Amgen hopes to avoid the expense of a complex study.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.